Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a positive outlook with a strong cash runway extending to 2029 and potential additional capital from Series A warrants. The Q&A section highlights robust clinical plans and market opportunities for OV329 without major concerns. While some management responses lacked clarity, the overall sentiment is positive due to the promising financial position and strategic focus on capital-efficient studies.
Key Financial Performance
Cash Position As of December 31, 2025, Ovid had $90.4 million in cash, cash equivalents, and marketable securities. This represents a significant financial resource for the company.
PIPE Financing Gross proceeds totaled $60 million before placement agent fees and offering expenses. This financing was led by Point72 and supported by top shareholders, providing additional capital to launch new programs without compromising existing ones.
Cash Runway With the net proceeds from the PIPE financing, the cash runway is expected to extend into the second half of 2028. Assuming the full exercise of Series A warrants, the cash runway is projected to extend well into 2029.
Potential Proceeds from Series A Warrants The clearance of OV4071 triggers a 30-day period for Series A warrants, potentially bringing additional capital exceeding $53 million to Ovid.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Regulatory clearance for OV4071: Received regulatory clearance for the first-ever oral KCC2 direct activator, OV4071, a quarter earlier than expected.
Safety and tolerability data for OV329: Announced safety and tolerability data for the 7 mg dose of OV329, with no serious adverse events or adverse events associated with the dose.
Pipeline expansion: Launching new programs for OV329 in infantile spasms and seizures associated with Tuberous Sclerosis Complex.
PIPE financing: Secured $60 million in PIPE financing led by Point72, with participation from top shareholders.
Series A warrants: Clearance of OV4071 triggers a 30-day period for Series A warrants, potentially bringing additional proceeds of over $53 million.
Cash runway: With PIPE financing and potential warrant exercise, cash runway extended well into 2029.
Clinical trial progress: Phase II randomized placebo-controlled trial for OV329 in focal onset seizures to begin in Q2 2026, along with an open-label photosensitivity study.
Focus on neuro hyperexcitability: All programs are focused on addressing neural hyperexcitation through small molecule programs.
KCC2 portfolio development: Advancing OV4071 and additional KCC2 direct activators, with a Phase I study for OV4071 starting in Q2 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: Forward-looking statements are subject to risks and uncertainties, including those discussed in the company's annual report and SEC filings. Regulatory clearance for OV4071 has been achieved in Australia, but further approvals in the U.S. and EU are pending.
Financial Risks: The company relies on PIPE financing and potential exercise of Series A warrants for additional capital. Failure to secure these funds could impact the cash runway and development programs.
Clinical Development Risks: The success of OV329 and OV4071 depends on achieving proof-of-concept and safety in clinical trials. Any adverse findings could delay or halt development.
Market Risks: Despite the potential of OV329, 40% of the epilepsy community remains uncontrolled with existing treatments, indicating a competitive and challenging market.
Operational Risks: The company is expanding its pipeline with new programs, which could strain resources and operational capacity if not managed effectively.
Safety and Efficacy Risks: Although OV329 has shown no serious adverse events, long-term safety and efficacy data are still required to ensure regulatory approval and market acceptance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Pipeline Progress: Ovid Therapeutics announced regulatory clearance for OV4071, the first-ever oral KCC2 direct activator, a quarter earlier than expected. Safety and tolerability data for the 7 mg dose of OV329, a next-generation GABA-aminotransferase inhibitor, showed no serious adverse events. The company plans to advance all programs to patient proof-of-concept studies with potential readouts through 2027.
New Clinical Programs: Ovid is launching new programs for OV329 in infantile spasms and seizures associated with Tuberous Sclerosis Complex. These programs are supported by additional capital from a PIPE financing and potential proceeds from Series A warrants, providing a cash runway into 2029.
Phase II Trials: A Phase II randomized placebo-controlled trial for OV329 in focal onset seizures will begin in Q2 2026. An open-label photosensitivity study will also be initiated later in 2026 to demonstrate anticonvulsant response.
Pediatric Programs: Ovid is developing a pediatric formulation of OV329 for infantile spasms and Tuberous Sclerosis Complex. Signal-finding and safety studies will be conducted, with potential for combined pivotal Phase II/III studies for registration.
KCC2 Activator Development: Phase I studies for OV4071 will begin in Q2 2026, followed by a ketamine challenge study later in the year. Proof-of-concept patient studies are expected to start late 2026 or early 2027. Additional KCC2 activators are in development.
Financial Outlook: Ovid has $90.4 million in cash as of December 31, 2025. A $60 million PIPE financing and potential proceeds from Series A warrants are expected to extend the cash runway into 2029.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you discuss the plans for OV329 and the visual monogram in the Phase II and placebo-controlled studies?
A:The ophthalmic and retinal monitoring will continue in the Phase II study and pivotal studies thereafter to ensure robust patient safety data. This is to demonstrate no structural or visual changes in the eye, aiming to avoid monitoring limitations seen with prior drugs like vigabatrin.
Q:Should we expect the response rate in the PPR study with OV329 to be similar to published studies on vigabatrin?
A:The PPR study is designed to demonstrate anticonvulsant effect and establish potential anticonvulsant activity at the desired doses. It is a capital-efficient and clinically sound method to assess anticonvulsant activity.
Q:Can you provide details on the planned Phase II design for OV329 in FOS and the rationale for the ketamine challenge study for OV4071?
A:The Phase II design targets adults with treatment-resistant focal onset seizures, using endpoints like percent reduction in seizures and monthly seizure reduction. The ketamine challenge study aims to show OV4071's brain penetration, GABAergic activity, and potential clinical symptom amelioration, supported by biomarkers.
Q:What type of patients will be enrolled in the open-label photosensitive epilepsy study, and how will it inform on focal onset versus other epilepsy types?
A:The study will enroll adults with diagnosed epilepsy and documented photosensitivity, using intermittent photo stimulation. It aims to confirm anticonvulsant activity in a modest and capital-efficient way, providing derisking data before full Phase II readouts.
Q:How will you approach differential pricing for OV329 across different populations?
A:Differential pricing will be based on the formulation and population served. For adult focal onset seizures, a capsule will be used, while pediatric populations with infantile spasms and Tuberous Sclerosis Complex will use a liquid or syrup formulation, allowing for appropriate and responsible pricing.
Q:Can you elaborate on the market size for TSC and IS, and the impact of visual issues with vigabatrin?
A:Sabril (vigabatrin) peaked at over $320 million in U.S. sales despite its visual safety concerns. A safe GABA-aminotransferase inhibitor like OV329 could have a larger market opportunity, especially if used earlier and longer in treatment.
Q:How many subjects in the 7 mg arm of OV329 reached the desired AUC threshold, and is there a rationale for exploring doses above 7 mg?
A:All subjects in the 7 mg arm reached the desired AUC threshold. There is no rationale for higher doses as the enzyme inhibition ceiling is around 60-65%, and the current doses achieve the desired pharmacology without additional adverse effects.
Q:Will additional preclinical data for the KCC2 program be presented at the upcoming R&D Day?
A:Yes, more preclinical data supporting biomarker strategy, indication selection, and the broad profile of OV4071 will be presented.
Q:What are the long-term clinical development plans for OV329 in focal onset seizures and other indications?
A:The focus is on building data to inform potential expansion into other epilepsies and indications. While refractory status epilepticus is supported by preclinical data, operational complexities make it a less immediate priority.
Q:When will we see the first signals from the TSC study, and what will they include?
A:The open-label TSC study will provide sequential updates, starting with older patients and moving to younger ones. It aims to establish safety, signal, and confirm dose modeling before initiating infantile spasms studies.
Q:What are the key endpoints for the PPR study, and how do they relate to seizure response?
A:Key endpoints include reductions in IPS frequencies inducing PPR, increased threshold frequency for PPR, and complete suppression of PPR. These provide confidence in anticonvulsant activity but are not equivalent to full Phase II efficacy data.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the breakout of sales for Sabril by indication, stating that Lundbeck never disclosed this information. Additionally, they did not provide a clear target for EEG marker changes in the PPR study or a definitive correlation between PPR response and seizure reduction.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
KCC
OV
Phase II
Sabril
Sclerosis Complex
Tuberous Sclerosis
activator
activity
addition
aminotransferase inhibitor
brain
clearance
concept
conviction
development
drug
epilepsy
event
generation
hand
indication
inhibition
mechanism
medicine
milligram dose
model
news
onset seizure
opportunity
patient
program
safety
signal
spasm
study
today
track
treatment
OVID Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
